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ABSTRACT
The “endo-symbiotic theory of mitochondrial evolution” states that mitochondrial 
organelles evolved from engulfed aerobic bacteria, after millions of years of symbiosis 
and adaptation. Here, we have exploited this premise to design new antibiotics 
and novel anti-cancer therapies, using a convergent approach. First, virtual high-
throughput screening (vHTS) and computational chemistry were used to identify novel 
compounds binding to the 3D structure of the mammalian mitochondrial ribosome. 
The resulting library of ~880 compounds was then subjected to phenotypic drug 
screening on human cancer cells, to identify which compounds functionally induce 
ATP-depletion, which is characteristic of mitochondrial inhibition. Notably, the top ten 
“hit” compounds define four new classes of mitochondrial inhibitors. Next, we further 
validated that these novel mitochondrial inhibitors metabolically target mitochondrial 
respiration in cancer cells and effectively inhibit the propagation of cancer stem-like 
cells in vitro. Finally, we show that these mitochondrial inhibitors possess broad-
spectrum antibiotic activity, preventing the growth of both gram-positive and gram-
negative bacteria, as well as C. albicans - a pathogenic yeast. Remarkably, these novel 
antibiotics also were effective against methicillin-resistant Staphylococcus aureus 
(MRSA). Thus, this simple, yet systematic, approach to the discovery of mitochondrial 
ribosome inhibitors could provide a plethora of anti-microbials and anti-cancer 
therapies, to target drug-resistance that is characteristic of both i) tumor recurrence 
and ii) infectious disease. In summary, we have successfully used vHTS combined 
with phenotypic drug screening of human cancer cells to identify several new classes 
of broad-spectrum antibiotics that target both bacteria and pathogenic yeast. We 
propose the new term “mitoriboscins” to describe these novel mitochondrial-related 
antibiotics. Thus far, we have identified four different classes of mitoriboscins, such 
as: 1) mitoribocyclines, 2) mitoribomycins, 3) mitoribosporins and 4) mitoribofloxins. 
However, we broadly define mitoriboscins as any small molecule(s) or peptide(s) that 
bind to the mitoribosome (large or small subunits) and, as a consequence, inhibit 
mitochondrial function, i.e., mitoribosome inhibitors.
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INTRODUCTION
Evidence is accumulating that increased 
mitochondrial biogenesis may play a critical role in the 
successful propagation and maintenance of the cancer 
stem-like cell (CSC) phenotype [1-9]. 
Analysis of transcriptional profiling data from 
human breast cancer samples (N = 28 patients) revealed 
that > 95 mRNA transcripts associated with mitochondrial 
biogenesis and/or mitochondrial translation are 
significantly elevated in cancer cells, as compared with 
adjacent stromal tissue [10, 11]. Remarkably, > 35 of these 
95 upregulated mRNA’s encode mitochondrial ribosomal 
proteins (MRPs) [11]. MRPs are the functional subunits 
of the mitochondrial ribosomes (mitoribosomes), which 
are responsible for the mitochondrial translation of 13 
protein components of the OXPHOS complex encoded by 
mitochondrial DNA. In this context, MRPS gene products 
are used to form the small subunit of the mitoribosome, 
while MRPL gene products are used to generate the large 
subunit of the mitoribosome [12-15].
Most of these 36 mitoribosome-related mRNA 
transcripts were elevated between 2- to 5-fold in human 
breast cancer cells, including seventeen members of the 
MRPS gene family (S7, S11, S12, S13, S14, S15, S17, 
S18A, S18B, S22, S26, S27, S28, S30, S31, S33, S35) and 
nineteen members of the MRPL gene family (L3, L9, L15, 
L16, L17, L18, L20, L22, L24, L33, L39, L40, L42, L46, 
L48, L49, L52, L54, L57) [11]. 
Proteomic analysis of human breast cancer stem-
like cells also revealed the significant over-expression 
of several mitoribosomal proteins, such as MRPL45 
and MRPL17, and 6 other proteins associated with 
mitochondrial biogenesis (HSPA9, TIMM8A, GFM1, 
HSPD1 [a.k.a., HSP60], TSFM, TUFM) [1]. Importantly, 
functional inhibition of mitochondrial biogenesis, using 
the off-target effects of certain bacteriostatic antibiotics, 
effectively ablated the propagation of CSCs, in 12 
cell lines representing 8 different tumor types (breast, 
DCIS, prostate, ovarian, pancreatic, lung, melanoma and 
glioblastoma) [3, 5]. Virtually identical results were also 
obtained with bonafide OXPHOS inhibitors (pyrvinium 
pamoate and atovaquone), providing additional 
complementary evidence that functional mitochondria 
are required for the propagation of CSCs [3, 16]. Taken 
together, these preliminary studies provide the necessary 
evidence that the development of novel mitoribosome 
inhibitors might be a beneficial approach for the more 
effective treatment of cancer patients.
Recently, the 3D structures of both the large 
(39S) and the small (28S) subunits of the mammalian 
mitoribosome (55S) have been resolved [17-22], allowing 
for the rationale molecular design of mitoribosome 
inhibitors.
Here, we used the known 3D structure of the large 
39S mammalian mitoribosome as a target to perform 
virtual high-throughput screening (vHTS). We coupled 
this computational chemistry approach with phenotypic 
drug screening, allowing for the functional identification 
and validation of novel compounds targeting mammalian 
mitoribosomes. The ability of these mitochondrial 
inhibitors to functionally prevent oxygen-consumption and 
halt ATP production was also demonstrated by metabolic 
flux analysis. Most importantly, these mitochondrial 
inhibitors effectively blocked the propagation of CSC, as 
predicted, providing proof-of-concept. 
Interestingly, we also show that these mitochondrial 
inhibitors behave as broad-spectrum antibiotics, which 
is consistent with the well-established hypothesis that 
mitochondria originally evolved from the engulfment of 
aerobic bacteria, approximately 1.5 billion years ago [23-
28]. This has important implications for more effectively 
combating the development of antibiotic-resistance.
RESULTS
Exploiting the evolutionary relationship between 
bacteria and mitochondria, to drive the discovery 
of new antibiotics and novel anti-cancer agents
The “Endo-symbiotic Theory of Mitochondrial 
Evolution” states that mitochondria originally evolved 
from aerobic bacteria that were incorporated into 
eukaryotic cells [23-28], during millions of years of 
adaptation (Figure 1). Consistent with this theory, we 
have recently shown that certain classes of well-known 
antibiotics that inhibit bacterial protein synthesis [29-
31], can also be used to successfully target mitochondrial 
protein translation, especially in cancer stem-like cells 
(CSCs) [32].
However, the converse of these observations 
should also be true. More specifically, new inhibitors of 
mitochondrial protein translation should also possess anti-
microbial activity. Here, to test this hypothesis directly, 
we used the known 3D structure of the mammalian 
mitochondrial ribosome (large subunit) to identify novel 
compounds that bind to it, in the context of virtual high-
throughput screening (i.e., in silico drug screening). Once 
potential binding partners were identified in silico, then 
these 880 compounds were subjected to phenotypic drug 
screening in vitro, to select positive hits that functionally 
induced ATP-depletion in MCF7 human breast cancer 
cells. Approximately 85% of cellular ATP is normally 
generated by OXPHOS in mitochondria, so ATP-depletion 
is a valid surrogate marker for mitochondrial inhibition. 
However, only compounds depleting ATP levels without 
prominent cytotoxicity were selected for further analysis.
These positive hits were then subjected to further 
validation, using the Seahorse metabolic flux analyzer, 
to confirm their mechanism of action as mitochondrial 
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inhibitors. Finally, these novel compounds were tested 
on six distinct bacterial and/or yeast strains to investigate 
if they possess anti-microbial activity. This overall 
experimental strategy is outlined schematically as a flow-
diagram in Figure 2. 
Identification and validation of novel inhibitors of 
the large mitochondrial ribosome
The resulting 880 compounds were first subjected 
to phenotypic drug screening at a concentration of 50 
µM, to identify which compounds functionally induce 
ATP-depletion, before inducing cell death. Subsequently, 
positive hits were re-screened at lower concentrations (25 
µM and 10 µM), to identify the top 10 compounds that 
most potently induced ATP-depletion.
Results from the ATP-depletion assay for the top 
10 hits identified from phenotypic drug screening are 
shown in detail in Figure 3. Briefly, MCF7 cells were 
treated with the hit compounds at 10 µM for 72 hours. 
Hoechst staining showed cell viability based on DNA 
staining, while measurement of ATP content revealed the 
effect of compounds on metabolic activity during the very 
same treatments. Compounds inhibiting mitochondrial 
metabolism were selected for further analysis. Hoechst 
staining and ATP content were also normalized to controls. 
Results were rank-ordered, as indicated, based on their 
ability to effectively deplete ATP, without inducing overall 
cell toxicity - as reflected by maintenance of viability and 
cell attachment. 
Comparison of the chemical structures of these top 
10 compounds identified 4 different drug classes, based 
on structural similarities, which are summarized in Figure 
4. Three compounds fall into Group 1, four compounds in 
Group 2, two compounds in Group 3, and one compound 
in Group 4. 
To validate the hypothesis that these compounds 
also target cancer stem-like cells (CSCs), the top 7 hits 
were compared in parallel for their ability to inhibit 
mammosphere formation in MCF7 cells. Importantly, 
5 of the 7 compounds tested significantly inhibited 
mammosphere formation, at a concentration of 5 µM 
Figure 1: The endo-symbiotic theory of mitochondrial 
evolution: Implications for modern drug development. 
Note that mitochondria originally evolved from engulfed aerobic 
bacteria, during millions of years of adaptation. A corollary of 
these findings is that many antibiotics also show mitochondrial 
side effects and effectively behave as inhibitors of mitochondrial 
protein translation (e.g., chloramphenicol, the tetracyclines and 
the erythromycins). Conversely, if we identify inhibitors of 
mitochondrial protein translation using mammalian cells, these 
drugs should also show anti-microbial activity, behaving as novel 
antibiotics. This would provide a new therapeutic strategy for 
efficiently generating novel drugs that target both mitochondria 
and bacteria, as well as pathogenic yeast strains. 
Figure 2: Schematic diagram illustrating our overall 
drug discovery strategy, employing both in silico drug 
discovery and phenotypic drug screening. 1. Virtual high-
throughput screening (vHTS) - We used the 3D structure of the large 
mammalian mitochondrial ribosome to screen a virtual collection of 
45,000 compounds and identified a subset of 880 compounds that 
“bind” in silico. 2. Phenotypic drug screening - The resulting 880 
compounds were then subjected to phenotypic drug screening at a 
concentration of 50 µM, to identify which compounds functionally 
induce ATP-depletion, before inducing cell death. Subsequently, 
positive hits were re-screened at lower concentrations (25 and 10 
µM), to identify the top ten compounds that most potently induced 
ATP-depletion. 3. Functional validation - The top hits were then 
further validated using metabolic flux analysis, to determine specific 
effects on oxygen consumption, to estimate their anti-mitochondrial 
activity. Mammosphere assays (for assessing potential anti-cancer 
stem cell activity) and cell viability assays were also carried out. 
Finally, the top three compounds were assessed for anti-microbial 
activity, to determine their minimum inhibitory concentration (MIC) 
and they were compared side-by-side with known antibiotics. 
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(Figure 5). For example, 23/G4 (Group 1) reduced 
mammosphere formation by 50% at this concentration. 
Similarly, 24/F9 (Group 2) and 24/D4 (Group 3), both 
reduced mammosphere formation by ~90%.
Based on this analysis, we next selected 3 top hits 
to assess their functional effects on overall viability in 
MCF7 cell monolayers and normal human fibroblasts 
(hTERT-BJ1 cells) (Figure 6). Interestingly, 23/G4 
(Group 1) reduced the viability of MCF7 cells by 70% at 
a concentration of 5 µM. However, 23/G4 had no effect on 
Figure 4: Chemical structures of the top 10 hits. The most promising top 10 hits of the phenotypic drug screen were organized 
into 4 groups based on chemical structure: Group 1: a) 23/E9 (BDI34121280); b) 23/G4 (BDH34061768); and c) 25/E3 (BDH34062170). 
In this group, we focused on characterizing the activity of 23/G4. Group 2: d) 24/F9 (BDH34136185); e) 24/B10 (LAS34137204); f) 24/
H6 (BDH34137234); and g) 25/B3 (BDH32350576). In this group, we focused on characterizing the activity of 24/F9. Group 3: h) 24/
D4 (BDH34137581) and i) 24/H9 (BDG34137236). In this group, we focused on characterizing the activity of 24/D4.Group 4: j) 26/H4 
(D264-0108).
Figure 3: Comparison of the top 10 hits using the ATP-depletion assay. The top ten hits were all evaluated at a concentration of 
10 µM, to determine their rank order potency, for their ability to deplete ATP levels. MCF7 cells were treated with the selected compounds 
of at 10µM for 72 hours. Hoechst staining showed cell viability based on DNA staining, while measurement of ATP content revealed the 
effects of the compounds on metabolic activity. Compounds targeting the inhibition of metabolism were selected. Hoechst staining and ATP 
content were normalized to controls. Results are shown as mean ± SEM (n = 4).
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the viability of hTERT-BJ1 cells, when tested at the same 
concentration. Thus, it is possible to identify compounds, 
such as 23/G4, that preferentially target CSCs and “bulk” 
cancer cells, but not normal fibroblasts. 
Next, we performed functional validation of the 3 
top hits using the Seahorse Analyzer, to quantitatively 
measure oxygen consumption rate (OCR) and extracellular 
acidification rate (ECAR). OCR is a surrogate marker for 
OXPHOS and ECAR is a surrogate marker for glycolysis 
and L-lactate production.
As predicted, 23/G4 (Group 1), 24/F9 (Group 2) 
and 24/D4 (Group 3) all dose-dependently inhibited 
mitochondrial oxygen-consumption in MCF7 cells, 
with 23/G4 being the most potent (Figures 7, 8 and 9). 
For example, 23/G4 reduced ATP levels by > 50% at a 
concentration of only 500 nM. In addition, 23/G4 reduced 
ATP levels by ~75% at 2.5 µM (Figure 7). Remarkably, 
treatment with 23/G4, at the same concentrations, had 
little or no effect on the overall cell viability of MCF7 
monolayers (Figure 6). Therefore, 23/G4 very effectively 
depleted ATP levels, without showing significant 
cytotoxicity. 
Interestingly, 23/G4 induced an increase in 
glycolysis rates by > 1.5-fold, while 24/F9 and 24/D4 both 
suppressed glycolysis. This could explain why 24/F9 and 
24/D4 were more potent than 23/G4 in the mammosphere 
assay, where 24/F9 and 24/D4 both reduced mammosphere 
formation by ~90% at a concentration of 5 µM (Figure 5). 
The rank order potency of the top 10 hits for their ability 
to reduce i) maximal respiration and ii) ATP production is 
shown in Figure 10. Note that the top 6 compounds in this 
regard were 23/G4, 25/B3, 24/H9, 24/F9, 23/E9 and 24/
H6, with 23/G4 being the most potent, yielding a > 75% 
reduction in ATP levels at 5 µM.
As EMT and cell invasion are phenotypic features 
associated with “stemness” and distant metastasis [33-35], 
we also evaluated the effects of these compounds on the 
ability of another more aggressive breast cancer cell line, 
namely MDA-MB-231, to undergo cell migration. Figure 
11 shows that 23/G4, 24/D4 and 24/F9 all inhibited cell 
migration by > 70%, at a concentration of 2.5 µM.
In summary, 23/G4 (Group 1) appears to be the most 
promising new lead compound, as it is more selective at 
targeting CSCs and cancer cells, while sparing normal 
Figure 5: Effects of 7 top hit compounds on 
mammosphere formation, representing 4 different 
structural groups or classes. Note that 5 of the 7 compounds 
evaluated significantly inhibited mammosphere formation, 
a measure of cancer stem cell activity, at a concentration of 5 
µM. Compounds 24/F9, 24/D4 and 23/G4 were among the most 
effective, with an IC-50 < 5 µM. Results are shown as the mean 
± SEM (n = 3). *** p < 0.001.
Figure 6: Effects of 3 top hit compounds on cell viability. A. MCF7 human breast cancer cells. B. hTERT-BJ1 normal human 
fibroblasts. The SRB assay was performed after 72 hours of treatment. Note that 23/G4 has no effect on normal fibroblasts at 5 µM. 
However, at the same concentration, 23/G4 reduces the viability of MCF7 breast cancer cells by > 70%. Thus, 23/G4 shows a degree of 
selectivity for cancer cells. Results are shown as mean ± SEM (n = 6). *** p < 0.001, * p < 0.05.
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Figure 7: Effects of compound 23/G4 on the metabolic activity of MCF7 human breast cancer cells. Oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) was measured using the Seahorse XFe96 Metabolic Flux Analyzer. Then data were 
normalized to protein content (SRB assay). Note that 23/G4 treatment reduced mitochondrial respiration significantly even at a dose as low 
as 500 nM (see panel A.) by markedly decreasing basal and maximal respiration, as well as ATP production (panel C.). Treatment with the 
highest dose (2.5 µM) resulted in increased glycolysis (panels B., D.). MCF7 cells were treated with 23/G4 compound for 72 hours. Results 
are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 8: Effects of compound 24/D4 on metabolic activity of MCF7 human breast cancer cells. Oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) was measured using the Seahorse XFe96 Metabolic Flux Analyzer. Then data 
were normalized to protein content (SRB assay). Note that treatment with compound 24/D4 (2.5 µM) showed a marked inhibition of 
mitochondrial respiration (see panels A., C.). The same dose significantly reduced glycolysis (panels B., D.). MCF7 cells were treated with 
compound 24/D4 for 72 hours. Results are shown as mean ± SEM (n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001.
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cells (Figure 6). Also, 23/G4 is the most potent hit 
compound that effectively reduces mitochondrial ATP 
levels and induces glycolysis. Most importantly, our 
results provide the necessary proof-of-concept that new 
mitochondrial inhibitors can be rapidly developed, by 
combining in silico drug design with phenotypic drug 
screening. 
Novel mitochondrial inhibitors function as broad-
spectrum antibiotics 
As mitochondria originally evolved from aerobic 
bacteria, over millions of years of evolution, we speculated 
that these new mitochondrial inhibitors would also behave 
as novel antibiotics. 
To test this hypothesis directly, we selected 3 top hit 
compounds (24/F9, 24/D4 and 23/G4) and examined their 
anti-microbial activity against two gram-positive bacterial 
strains (Staph. aureus and Strep. pyogenes) and three 
gram-negative bacterial strains (E. coli, P. aeruginosa, 
K. pneumoniae), as well as the pathogenic yeast strain C. 
albicans. 
The inhibition ratios of the selected compounds, 
against pathogenic strains, were calculated by serial 
dilution. The average of three inhibition zone diameter 
measurements was compared against commercial drugs, 
using the Kirby-Bauer method. 
Table 1: Gram-Positive Bacterial Antibiotic Sensitivity. 
The anti-bacterial activity of three hit compounds (24/F9, 24/D4 and 23/G4) was compared to known antibiotics, across two 
different gram-positive bacterial strains (Staph. aureus and Strep. pyogenes). S, sensitive; I, intermediate; R, resistant. 
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Table 2: Gram-Negative Bacterial Antibiotic Sensitivity.
The anti-bacterial activity of three hit compounds (24/F9, 24/D4 and 23/G4) was compared to known antibiotics, across three 
different gram-negative bacterial strains (E. coli, P. aeruginosa, K. pneumoniae).  S, sensitive; I, intermediate; R, resistant.
Table 3: Minimum Inhibitory Concentrations (MIC): 5 Bacterial Strains and 1 Pathogenic Yeast.
The anti-microbial activity of three hit compounds (24/F9, 24/D4 and 23/G4) was compared to known antibiotics, using five 
different bacterial strains (Staph. aureus, Strep. pyogenes, E. coli, P. aeruginosa, K. pneumoniae) and one pathogenic yeast/
fungus (C. albicans). Note that compound 23/G4 showed the greatest broad-spectrum activity and potency, as compared with 
compound 24/F9 and 24/D4.
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Final interpretation of the measurements enabled 
all of the bacterial strains tested to be grouped into three 
categories (Sensitive, Intermediate and Resistant) as 
summarized in Table 1 and 2. No growth inhibition was 
seen in the control (DMSO) (data not shown). Tables 1 and 
2 illustrate that all five bacterial strains tested are sensitive 
to the 3 hit compounds (24/F9, 24/D4 and 23/G4). 
Therefore, in order to determine the minimal 
inhibitory concentration (MIC) for 24/F9, 24/D4 and 
23/G4, the broth dilution method was performed. As 
expected, the MIC determination results were in good 
agreement with the disc-diffusion susceptibility test. 
Table 3 shows the MIC determination results obtained as 
compared to known antibiotics, against the tested bacterial 
strains and C. albicans. Importantly, note that compound 
23/G4 showed the greatest broad-spectrum activity and 
potency, as compared with compounds 24/F9 and 24/D4.
Finally, Table 4 shows that Methicillin-resistant 
Staphylococcus aureus (MRSA) is also sensitive to 23/
G4 and 24/D4. We confirmed that this strain of MRSA 
was indeed resistant to amoxicillin, as predicted. Thus, 
it is possible to successfully use this new drug discovery 
strategy employing human cancer cells, to isolate new 
antibiotics that can target drug-resistant bacteria, such as 
MRSA. 
DISCUSSION
Discovery of the mitoriboscins: targeting the 
mitochondrial ribosome
Here, we have used state-of-the art computational 
chemistry to select novel compounds that bind to the 
3D structure of the large subunit of the mammalian 
mitochondrial ribosome. Out of the 45,000 compounds 
tested, approximately 880 showed promising results, 
yielding a hit rate of 2%. To validate their functional 
ability to target mitochondria in vivo, we next performed 
phenotypic drug screening in human breast cancer cells 
(MCF7 cells). Using this approach, we selected the top 
Figure 9: Effects of compound 24/F9 on metabolic activity of MCF7 human breast cancer cells. Oxygen consumption 
rate (OCR) and extracellular acidification rate (ECAR) was measured using the Seahorse XFe96 Metabolic Flux Analyzer. Then data 
were normalized to protein content (SRB assay). Treatment with compound 24/F9 showed dose-dependent reduction of mitochondrial 
respiration, which was highest at 2.5 µM (panels A., C.). Inhibition of glycolysis was detected after treatment at the highest concentration 
(2.5 µM) of 24/F9. MCF7 cells were treated with compound 24/F9 for 72 hours. Results are shown as mean ± SEM (n = 6). * p < 0.05, ** 
p < 0.01, *** p < 0.001.
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10 hit compounds (10/880 = 1%) that effectively depleted 
cellular ATP levels. These top 10 hit compounds were then 
subjected to further validation using the Seahorse XFe96, 
to measure mitochondrial oxygen consumption and 
glycolysis. This approach allowed us to rank-order these 
top 10 hits, identifying the compound 23/G4 as the most 
potent (1/45,000 = 0.00002 = 0.002 %). Notably, 23/G4 
inhibited mitochondrial ATP production in MCF7 cells, 
with an IC-50 of approximately 500 nM. Remarkably, 
23/G4 showed no cytotoxicity against normal human 
fibroblasts, even at a concentration (5 µM) that reduced 
cancer cell viability by > 70% (Figure 6). Importantly, the 
top hit compounds that we identified also potently inhibited 
CSC propagation and cancer cell migration, all in the low 
micro-molar range. Finally, we also showed that 3 of these 
top hit compounds also behave as antibiotics, inhibiting 
the growth of pathogenic bacteria and yeast. Importantly, 
23/G4 and 24/D4 were also effective against MRSA. 
Figure 10: Comparative metabolic flux analysis of the top 10 hit compounds in MCF7 cells. A. Maximal respiration. B. 
ATP production. Measurements were made after 48 hours of treatment of MCF7 cells with a given compound, at a concentration of 5 μM. 
Note that compound 23/G4 most significantly reduces both i) ATP production (by > 70%) and ii) maximal respiration (by > 60%). Oxygen 
consumption rates (OCR) were measured using the Seahorse XFe96 and then data were normalized for protein content (SRB assay). 
Maximal respiration and ATP-linked respiration data were calculated, normalized to control values and were plotted as percent control. 
Results are shown as mean ± SEM (n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001. 
Figure 11: Effects of 3 top hit compounds on cell migration. MDA-MB-231 cells were subjected to cell migration assays. 23/
G4, 24/F9 and 24/D4 all significantly reduced cell migration, at concentrations of 1 and 2.5 µM. More specifically, 23/G4, 24/D4 and 24/
F9 inhibited cell migration by > 70%, at a concentration of 2.5 µM.
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Thus, we propose the new term mitoriboscins, to describe 
these mitochondrial-related antibiotics. Moreover, the 4 
classes of mitoriboscins that we describe here, we have 
designated as 1) mitoribocyclines, 2) mitoribomycins, 3) 
mitoribosporins and 4) mitoribofloxins (Figure 12). We 
generally define mitoriboscins as any small molecule that 
binds to the mitoribosome (large or small subunits) and, as 
a consequence, inhibits mitochondrial function.
Although the novel compounds that we identified 
here are relatively potent, we envision that further 
modifications will be required to better optimize their 
ability to i) disrupt mitochondria in CSCs and ii) to 
halt the growth of micro-organism(s), for the treatment 
of oncologic and infectious diseases respectively. 
Nevertheless, our results provide the necessary proof-of-
principle that it is possible to identify new antibiotics to 
target pathogenic bacteria and yeast, by employing ATP 
production in human cancer cells as a simple phenotypic 
screening tool (Figure 13). 
Figure 12: Mitoriboscins: Four new classes of mitochondrial inhibitors. The structures of 23/G4, 24/F9, 24/D4 and 26/H4 are 
shown, which now define 4 newly discovered classes of small molecules. These novel molecules were identified because of their structural 
and functional mitochondrial inhibitory activity in human cancer cells. As such, this convergent screening approach will undoubtedly yield 
other classes of new antibiotics, as well novel anti-cancer agents. We specifically define mitoriboscins as any small molecule that binds to 
the mitoribosome (large or small subunits); this binding activity ultimately inhibits mitochondrial function.
Table 4: Minimum Inhibitory Concentrations (MIC): MRSA versus MSSA.
The anti-microbial activity of three hit compounds (24/F9, 24/D4 and 23/G4) was compared to known 
antibiotics, using two different bacterial strains of Staph. aureus,  MRSA (methicillin-resistant Staph. 
aureus) and MSSA (methicillin-sensitive Staph. aureus). Note that MRSA is resistant to amoxicillin, 
as expected.
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The mitoribosins: therapeutic use to combat 
ageing and extend healthspan
Interestingly, genetic inhibition of mitochondrial 
protein translation has also been shown to have beneficial 
“side-effects”, such as the effective slowing of the aging 
process and increased lifespan in model organisms. 
Houtkooper et al., 2013, showed that lower steady-
state levels of Mrps5 (a mitoribosomal protein) were 
strongly functionally correlated with longer murine 
lifespan, resulting in a significant increase of ~250 days 
[36]. In addition, selective knock-down of Mrps5 in C. 
elegans dramatically increased lifespan. Importantly, 
Mrps5 knock-down worms showed significant decreases 
in mitochondrial respiration and ATP production [36]. 
Similarly, knock-down of the worm homologs of 
mitochondrial complex I, III, IV and V, as well as several 
TCA cycle enzymes, all robustly extended lifespan, further 
implicating reduced OXPHOS activity and lower ATP 
levels as the mechanism [37-39]. Finally, pharmacological 
inhibition of mitochondrial biogenesis (using the off-target 
side-effects of doxycycline), also significantly increased 
lifespan in C. elegans [36]. Thus, lower doses of the 
mitoriboscins could potentially be used to therapeutically 
target the aging process, to extend healthspan (Figure 13). 
Further studies will be required to explore this intriguing 
area of investigation. 
MATERIALS AND METHODS
Materials
MCF7 and MDA-MB-231 cells were purchased 
from the ATCC (American Type Culture Collection). 
Gibco-brand cell culture media (DMEM and DMEM/
F12) was purchased from Life Technologies. The top 6 hit 
compounds were custom-synthesized in larger quantities 
by ASINEX Corp., and compound D264-0108 (26/H4) 
was custom-synthesized by ChemDiv Inc. 
Bacterial and fungus strains
The strains Escherichia. coli (ATCC 25922), 
Klebisella pneumoniae (ATCC 13883), Pseudomonas 
aeruginosa (ATCC 27853), Staphylococcus aureus MSSA 
(ATCC 25923), Staphylococcus aureus MRSA (ATCC 
43300), Streptococcus pyogenes (ATCC 19615) and 
Candida Albicans (ATCC 13883) were provided by Remel 
Microbiology (Thermo Fisher). The cells were grown in 
Müller-Hinton broth II (MHB; Difco, Detroit, MI, USA) 
containing 2g/l beef infusion solids, 17.5 g/l casein 
hydrolysate, 1.5 g/l starch. The final pH was adjusted to 
7.4.
Virtual high-throughput screening (vHTS)
Compounds were selected from a small molecule 
screening collection of 45,000 compounds. Initial virtual 
high-throughput screening (vHTS) used the eHiTS 
screening program [40] to identify the top 5,000 ranked 
compounds based on predicted binding affinity to the 
large subunit (39S) of the mammalian mitoribosome [21]. 
To efficiently perform the docking, a series of clip files 
was prepared spanning the entire protein structure and the 
virtual library docked at each of the clip files. Consensus 
scoring of these top 5,000 compounds was carried out 
using AutoDock 4.2 [41], based on using the same general 
binding site for each compound predicted from the eHiTS 
screen. A total of 880 compounds performing well in these 
analysis steps were then selected for phenotypic drug 
screening.
Phenotypic drug screening, with a metabolic ATP-
depletion assay
MCF7 cells (6,000 cells/well) were plated into 
black clear-bottom 96-well plates and incubated overnight 
before treatment. The resulting 880 compounds first 
identified by vHTS were then subjected to phenotypic drug 
screening at a concentration of 50 µM, to identify which 
compounds functionally induce ATP-depletion, before 
Figure 13: Practical uses of the mitoriboscins: 
Targeting mitochondria. We propose that mitoriboscins will 
be therapeutically useful for the treatment of a variety of human 
diseases, including cancers and infectious illnesses, caused by 
pathogenic bacteria and fungi. In addition, we speculate that 
mitoriboscins may be helpful in the context of chronological 
aging, for either extending lifespan or healthspan. Thus, 
mitoriboscins will have anti-cancer, anti-microbial and anti-
aging properties. 
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inducing cell death. Subsequently, positive hits were re-
screened at lower concentrations (25 µM and 10 µM), to 
identify the top 10 compounds that most potently induced 
ATP-depletion. Compounds were tested after 72 hours of 
incubation and experiments were performed in duplicate. 
After treatment, media was aspirated from the wells 
and plates were washed with warm PBS (supplemented 
w/ Ca2+ and Mg2+). Then, cells were incubated with a 
Hoechst 33342 (Sigma) staining solution (10 µg/ml) for 
30 min and washed with PBS (to estimate cell viability). 
Fluorescence was read with a plate reader using excitation/
emission wavelenghts at 355/460-nm. Then, the CellTiter-
Glo luminescent assay (Promega) was performed to 
measure metabolic activity (ATP content) in the very 
same wells that were treated with a given compound. 
Assays were performed according to the manufacturer’s 
protocol. Fluorescence intensity (Hoechst staining) and 
luminescence intensity (ATP content) was normalized 
to vehicle-alone treated controls and were displayed as 
percent control for comparison. 
Cell viability assay
The Sulphorhodamine (SRB) assay is based on the 
measurement of cellular protein content. After treatment 
for 72h in 96-well plates, cells were fixed with 10% 
trichloroacetic acid (TCA) for 1h in the cold room, and 
were dried overnight at room temperature. Then, cells 
were incubated with SRB for 15 min, washed twice with 
1% acetic acid, and air dried for at least 1h. Finally, the 
protein-bound dye was dissolved in a 10 mM Tris, pH 8.8, 
solution and read using the plate reader at 540-nm.
Mammosphere formation assays
A single cell suspension of MCF7 cells was prepared 
using enzymatic (1x Trypsin-EDTA, Sigma Aldrich) and 
manual disaggregation (25 gauge needle) [42]. Cells were 
then plated at a density of 500 cells/cm2 in mammosphere 
medium (DMEM-F12/ B27 / 20-ng/ml EGF/PenStrep) 
in non-adherent conditions, in culture dishes coated with 
(2-hydroxyethylmethacrylate) (poly-HEMA, Sigma). Cells 
were grown for 5 days and maintained in a humidified 
incubator at 37°C at an atmospheric pressure in 5% (v/v) 
carbon dioxide/air. After 5 days in culture, spheres > 50 
μm were counted using an eye-piece graticule, and the 
percentage of cells plated which formed spheres was 
calculated and is referred to as percent mammosphere 
formation, normalized to vehicle-alone treated controls. 
Mammosphere assays were performed in triplicate and 
repeated three times independently.
Seahorse XFe96 metabolic Flux analysis
Extracellular acidification rates (ECAR) and real-
time oxygen consumption rates (OCR) for MCF7 cells 
were determined using the Seahorse Extracellular Flux 
(XF96) analyzer (Seahorse Bioscience, MA, USA). 
MCF7 cells were maintained in DMEM supplemented 
with 10% FBS (fetal bovine serum), 2 mM GlutaMAX, 
and 1% Pen- Strep. 5,000 cells per well were seeded into 
XF96-well cell culture plates, and incubated overnight at 
37°C in a 5% CO2 humidified atmosphere. After 24h, cells 
were treated with the top three hit compounds at various 
concentrations (or vehicle alone). After 72h of treatment, 
cells were washed in pre-warmed XF assay media (for 
OCR measurement, XF assay media was supplemented 
with 10mM glucose, 1mM Pyruvate, 2mM L-glutamine 
and adjusted at pH 7.4). Cells were then maintained in 
175 μL/well of XF assay media at 37°C, in a non-CO2 
incubator for 1h. During incubation, 25 μL of of 80mM 
glucose, 9μM oligomycin, 1M 2-deoxyglucose (for 
ECAR measurement) and 25 μL of 10μM oligomycin, 
9μM FCCP, 10μM rotenone, 10μM antimycin A (for OCR 
measurement) in XF assay media was loaded into the 
injection ports of the XFe-96 sensor cartridge. During the 
experiment, the instrument injected these inhibitors into 
the wells at a given time point, while ECAR/OCR was 
measured continuously. ECAR and OCR measurements 
were normalized by protein content (Sulphorhodamine 
B assay). Data sets were analyzed by XFe-96 software, 
using one-way ANOVA and Student’s t-test calculations. 
All experiments were performed in triplicate.
Cell migration assay
The migration of MDA-MD-231 cells was carried 
out, essentially as we previously described, with minor 
modifications [43]. 
Gram (+ve) and gram (-ve) susceptibility testing
The antimicrobial susceptibilities of the novel 
compounds were evaluated using the Kirby-Bauer disc-
diffusion method [44-46], performed according to CLSI 
guidelines and results were interpreted using CLSI 
breakpoints [47-48]. Antibiotics disks against gram(+ve) 
and gram(-ve) bacterias (from Oxoid™) were used as 
positive controls. All new componds (24/D4, 24/F9, 
23/G4) were prepared by dissolving them in dimethyl 
sulfoxide (DMSO, from Sigma/Aldrich Company; St. 
Louis, MO, USA) and were utilized to impregnate the 
Blank Antimicrobial Susceptibility Disks (Oxoid™). 
Specifically, overnight cultures of bacteria tested were 
adjusted to a turbidity of 0.5 McFarland standards (106 
CFU/ml) before inoculation onto agar plates with sterile 
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cotton swabs. A cotton swab dipped in the cell culture 
was streaked onto an agar plate surface in such a way 
as to obtain a uniform layer of bacteria across the whole 
surface. After 10-15 min, the antibiotics disks or novel 
compounds disks were laid on the inoculated surface of the 
agar plates; then, all agar plates were incubated at 37°C, 
overnight. The diameters of inhibition were measured and 
susceptibility was expressed in terms of resistance (R), 
moderate susceptibility (I) and susceptibility (S). Agar 
plates inoculated with bacteria tested with impregnated 
DMSO disks were used as controls. The result obtained 
on single bacteria strain was confirmed by Sensi test gram-
positive and Sensi test-gram-negative kits (Liofilchem 
s.r.l.). Disc-diffusion susceptibility test was performed in 
triplicate and repeated three times independently.
Anti-microbial activity and MIC values 
determination
The minimal inhibitory concentration (MIC) of 
the antibacterial compounds was determined using the 
broth dilution method, according to CLSI guidelines 
[48]. Briefly, a solution content the new compounds (or 
several antibiotics used as positive control) was diluted, 
serially, with MHB medium. Then, the suspensions of 
the microorganisms, prepared from overnight cultures of 
bacteria in the MHB medium, at a concentration of 106 cfu 
x ml-1, were added to each dilution in a 1:1 ratio McFarland 
standards were used as a reference to adjust the turbidity 
of microorganism suspensions. Growth (or lack thereof) 
of the microorganisms was determined after incubation 
for 24 h at 37 °C by turbidimetry (wavelength of 600 
nm). MIC 50 and MIC 99 were defined as the minimum 
inhibitory concentration of the compound required for 
50% and 99% inhibition of bacterial growth. The negative 
control tubes did not contain bacterial inoculum while 
the positive control tubes containing only DMSO, were 
antibiotics or compounds free. The susceptibility test by 
measurement of MIC was performed in triplicate and 
repeated three times independently.
Statistical analyses
Statistical significance was determined using the 
Student’s t-test, values of less than 0.05 were considered 
significant. Data are shown as the mean ± SEM, unless 
stated otherwise.
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